1	Title: Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase and
2	ethanolamides metabolism with Alzheimer's disease
3	
4	Author: Kamil Borkowski ¹ , Theresa L. Pedersen ² , Nicholas T. Seyfried ³ , James J. Lah ⁴ , Allan I.
5	Levey ⁴ , Chadwick M. Hales ⁴ , Eric B. Dammer ³ , Colette Blach ⁵ , Gregory Louie ⁶ Rima
6	Kaddurah-Daouk ⁷ , John W. Newman ^{1,8,9} and Alzheimer's Disease Metabolomics Consortium
7	
8	
U	
9	Author affiliations:
10	1 – West Coast Metabolomics Center, Genome Center, University of California Davis, Davis,
11	CA 95616, USA.
12	2 – Dept Food Science and Technology, University of California - Davis, Davis, CA 95616,
13	USA.
14	3 – Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322,
15	USA
16	4 – Department of Neurology, Emory University, Atlanta, GA, 30329 USA
17	5 – Duke Molecular Physiology Institute, Duke University, Durham, NC, 27708 USA
18	6 – Department of Psychiatry and Behavioral Sciences, Duke University, Durham NC 27708,
19	USA.

20	7 – Department of Psychiatry and Behavioral Sciences, Duke Institute for Brain Sciences and
21	Department of Medicine, Duke University, Durham NC 27708, USA.
22	8 - Western Human Nutrition Research Center, United States Department of Agriculture -
23	Agriculture Research Service, Davis, CA 95616, USA.
24	9 – Department of Nutrition, University of California - Davis, Davis, CA 95616, USA.
25	
26	* Corresponding author: kborkowski@ucdavis.edu
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	

39 Abstract

Alzheimer's disease shares inflammatory origin with cardiometabolic disorders. Lipid mediators, 40 41 including oxylipins, endocannabinoids, bile acids and steroids are potent regulators of 42 inflammation, energy metabolism and cell proliferation with well-established involvement in cardiometabolic diseases. However, their role in Alzheimer's disease is poorly understood. In the 43 44 current study we provide comprehensive analysis of plasma and CSF lipid mediators in a casecontrol comparison of patients with Alzheimer's disease, utilizing a targeted quantitative mass 45 spectrometry approach. In both plasma and CSF, we observed Alzheimer's disease patients to 46 have elevated components of cytochrome P450/soluble epoxide hydrolase pathway and lower 47 48 levels of fatty acids ethanolamides, when compared to the healthy controls. Multivariate analysis 49 revealed that circulating metabolites of soluble epoxide hydrolase together with ethanolamides 50 are strong and independent predictors for Alzheimer's disease. Both metabolic pathways are potent regulators of inflammation with soluble epoxide hydrolase being reported to be 51 52 upregulated in the brains of Alzheimer's disease patients. This study provides further evidence for the involvement of inflammation in Alzheimer's disease and argues for further research into 53 the role of the cytochrome P450/soluble epoxide hydrolase pathway and fatty acid ethanolamides 54 in this disorder. Further, these findings suggest that a combined pharmacological intervention 55 targeting both metabolic pathways may have therapeutic benefits for Alzheimer's disease. 56

- 57
- 58

59

61 Introduction

Risk factors for Alzheimer's disease (AD) include cardiometabolic disorders, low-grade systemic inflammation and altered lipid and energy metabolism [1-3]. Lipid mediators are lipid derived signaling molecules that regulate both acute and low-grade systemic inflammation and energy metabolism along with other processes [4]. Circulating lipid mediators have been implicated in the pathogenesis of cardiometabolic diseases [5-7], however, their involvement in AD is still not well described.

68 Four important families of such lipid mediators readily detected in the circulation are the oxygenated polyunsaturated fatty acids (i.e. oxylipins), the endogenous cannabinoid receptor 69 activators and their structural equivalents (i.e. endocannabinoids, including monoacylglycerols 70 71 and ethanolamides), bile acids and steroids. Oxylipins are mainly oxygenated products of polyunsaturated fatty acids (PUFAs) generated via 4 main pathways: cyclooxygenases (COX), 72 generating mainly prostaglandins; lipoxygenases (LOX), generating mainly hydroxy-fatty acids, 73 74 including leukotrienes and lipoxins; cytochrome P450 (CYP) and soluble epoxide hydrolase (sEH), generating epoxy-fatty acids and dihydroxy fatty acids respectively [4], and reactive 75 oxygen-mediated formation of prostanoids and hydroxy-fatty acids (REF). Products from these 76 pathways exhibit both pro- and anti-inflammatory actions (REF). Endocannabinoids are mainly 77 fatty acids esters and amides, which are ligands for the cannabinoid receptors CB1 and CB2, the 78 79 transient potential vanilloid receptor TRPV1 and G- protein-coupled receptor GPR55 [8], all highly expressed in the central nervous system [9]. Endocannabinoids regulate energy 80 81 metabolism [8] and are generally consider anti-inflammatory [10]. Bile acids (BA) are generated 82 by the liver as primary bile acids and secreted into the gut to aid in lipid digestion, and they are further metabolized by the gut microbiome form secondary bile acids [11]. After reabsorption 83

from the gut into the blood stream, BAs regulate energy metabolism with different potency
between primary and secondary species [12].

86 Changes in circulating lipid mediators in relation to AD were previously reported. 87 Particularly, several oxylipins of the acute inflammation pathway were reportedly elevated in AD [13, 14] and pro-resolving (quenching activated inflammatory singal) lipid mediators have 88 89 been suggested as potential treatment for AD [15]. Specific changes in bile acids metabolism, including a decrease in primary and an increase in secondary metabolites were also observed in 90 91 AD subjects [16] and differences in bile acids clearance for cholesterol pathway were reported in 92 AD [17]. Notably, bile acids and some steroids manifest neuroprotective functions through activation of steroid receptors [18]. However, a comprehensive analysis of the AD related 93 changes in circulating lipid mediators is lacking and reports of lipid mediators in cerebrospinal 94 fluid (CSF) are minimal. In the current work we utilize plasma and CSF samples of AD patients 95 and cognitively normal controls from the Emory Goizueta Alzheimer's Disease Research Center 96 (ADRC). Using a case control approach, we provide comprehensive analysis of AD-associated 97 changes in both circulating and CSF lipid mediators, including major classes of oxylipins, 98 endocannabinoids, bile acids and some steroids, covering multiple aspects of inflammatory 99 100 cascades and regulators of energy metabolism. Moreover, to minimalize the bias caused by postprandial fluctuation in plasma lipids, the fasting state of opportunistically collected samples 101 was estimated using a novel predictive model that uses levels of circulating lipid mediators [19]. 102

104 Materials and methods

Subjects: All participants from whom plasma and CSF samples were collected provided 105 106 informed consent under protocols approved by the Institutional Review Board at Emory 107 University. Cohorts included the Emory Healthy Brain Study (IRB00080300), Cognitive Neurology Research (IRB00078273), and Memory @ Emory (IRB00079069). All protocols 108 109 were reviewed and approved by the Emory University Institutional Review Board. All patients received standardized cognitive assessments (including Montreal Cognitive Assessment 110 (MoCA)) in the Emory Cognitive Neurology clinic, the Emory Goizueta Alzheimer's Disease 111 112 Research Center (ADRC) and affiliated Emory Healthy Brain Study (EHBS) [20]. All diagnostic data were supplied by the ADRC and the Emory Cognitive Neurology Program. CSF was 113 collected by lumbar puncture and banked according to 2014 ADC/NIA best practices guidelines. 114 All CSF samples collected from research participants in the ADRC, Emory Healthy Brain Study, 115 and Cognitive Neurology clinic were assayed using the INNO-BIA AlzBio3 Luminex assay at 116 AKESOgen (Peachtree Corners, GA). AD cases and healthy individuals were defined using 117 established biomarker cutoff criteria for AD for each assay platform [21, 22]. In total, plasma 118 samples were available for 148 AD patients and 133 healthy controls and CSF samples were 119 120 available for 150 AD patients and 139 healthy controls. Plasma and CSF sample collection overlap (both plasma and CSF collected at the same day) was 145 for AD group and 133 for the 121 122 control group. Cohort information is provided in Table S1.

123

Quantification of lipid mediators: Plasma concentrations of non-esterified PUFA, oxylipins,
endocannabinoids, a group of non-steroidal anti-inflammatory drugs (NSAIDs) including
ibuprofen, naproxen, acetaminophen, a suite of conjugated and unconjugated bile acids, and a

series of glucocorticoids, progestins and testosterone were quantified in 50µL of plasma by 127 liquid chromatography tandem mass spectrometry (LC-MS/MS) after protein precipitation in the 128 presence of deuterated metabolite analogs (i.e. analytical surrogates) [23]. CSF analyses were 129 performed with 100µL samples prepared as previously reported for the analyses of sweat [24] 130 and analyzed as reported for plasma. All samples were processed with rigorous quality control 131 132 measures including case/control randomization, and the analysis of batch blanks, pooled matrix replicates and NIST Standard Reference Material 1950 - Metabolites in Human Plasma (Sigma-133 Aldrich, St Louis, MO). Extraction batches were re-randomized for acquisition, with method 134 135 blanks and reference materials and calibration solutions scattered regularly throughout the set. Instrument limits of detection (LODs) and limits of quantification (LOQs) were estimated 136 according to the Environmental Protection Agency method (40 CFR, Appendix B to Part 136 137 138 revision 1.11, U.S. and EPA 821-R-16-006 Revision 2). These values were then transformed into sample nM concentrations by multiplying the calculated concentration by the final sample 139 volume and dividing by the volume of sample extracted. A complete analyte list with plasma 140 LODs and LOQs have been reported [23]. The majority of analytes were quantified against 141 analytical standards with the exception of eicosapentaenoyl ethanolamide (EPEA), palmitoleoyl 142 143 ethanolamide (POEA), and the measured PUFAs [i.e. linoleic acid (LA); alpha-linolenic acid (aLA); arachidonic acid (AA); eicosapentaenoic acid (EPA); docosahexaenoic acid (DHA)]. For 144 145 these compounds, area counts were recorded, adjusted for deuterated-surrogate responses and the 146 relative response factors were expressed as the relative abundance across all analyzed samples. Reported monoacylglycerols (MAGs) are the sum of 1- and 2-acyl isomers, due to isomerization 147 148 during sample processing.

Fasting state assessment and sample selection: Many of the CSF and plasma samples from AD 150 patients were collected following additional research consent in the course of patients' clinical 151 evaluations. Lumbar puncture procedures were nearly all scheduled in the morning, but fasting 152 was not mandated in these individuals. Therefore, fasting state of the samples was estimated 153 using previously published predictive equation, based on the raw plasma levels of 12(13)-154 155 EpOME, GCDCA and NO-Gly [19]. Only subjects with the probability of the fasting state > 60% were used for the plasma analysis. All subjects were used to compare lipid mediators level 156 in CSF. CSF was reported not to manifest postprandial lipid fluctuations [25], additionally, 157 158 comparing predicted fated to predicted non-fasted AD subjects reveal minimal differences in only 2 metabolites (Table S2). 159

160

Statistical analysis: All statistical tests were performed using JMP Pro 14 (JMP, SAS institute, 161 Carry, NC). Prior to analysis, data were tested for outliers using the robust Huber M test and 162 163 missing data were imputed using multivariate normal imputation for variables which were at least 75% complete. The imputed numbers constitute less than 3% of the data for both plasma 164 165 and CSF. Imputation facilitated multivariate data analysis and non-imputed data were used for univariate approaches. Additionally, variables were normalized, centered, and scaled using 166 Johnson's transformation, with normality verification using the Shapiro-Wilk test. The difference 167 168 between the control and the AD group were assessed using t-test with gender, age, and race as covariates. Additionally, two-way ANOVA was used to test for the gender x group and race x 169 170 group interactions. In case of significant interaction, the group effect was tested separately for 171 the interacting factor. Correlations between MoCA score and lipid mediators were assessed using Spearman's rank order correlation, to account for non-linear associations. This analysis was 172

173performed using only AD subjects, stratified by the assessed fasting state for plasma. CSF174samples were analyzed without fasting state stratification. Multiple comparison control was175accomplished with the false discovery rate (FDR) correction method of Benjamini and Hochberg176with a q =0.2 [26].

Predictive models for AD were prepared using a combination of bootstrap tree and 177 178 stepwise logistic regression modeling. Prior to analysis, subjects were randomly split into 179 training (70%) and validation (30%) cohorts. Variables most frequently appearing in the models 180 were identified by bootstrap tree: Number of layers = 50; split per tree = 3, bootstrap sampling 181 rate for variables and subjects = 1. A variable contribution scree plot was generated using variable rank and the likelihood ratio of chi-square. The scree plot was used to determine a 182 183 likelihood ratio of chi-square cutoff value for variables contributing to the model. Selected variables were then subjected to stepwise logistic regressions. A stepwise analysis was 184 performed with the maximal validation r^2 as the model stopping criteria, or if an additional step 185 increased the Bayesian information criteria (BIC). Variables selected by the sptepwise approach 186 were then used to build the model using logistic regression. Metabolites that the model 187 contribution p-value < 0.05 were excluded, to ensure the strongest model with the minimal 188 189 number of predictors.

190Partial least square discriminant analysis (PLA-DA) was used to integrate AD related191differences in metabolite levels between plasma and CSF. PLS-DA model was built using the192nonlinear iterative partial least squares algorithm with K-Fold variation method (k =7) and193included 235 variables from plasma and CSF, including metabolite levels and informative194metabolite ratios. For the clarity purpose, only variables with a variable importance in projection195(VIP) score > 1.4 we displayed on the loading plot.

Correlation between CSF and plasma metabolites was assessed using Spearman's rankorder correlation.

198

199 Results

200 *Fasting state assessment*: Analysis of opportunistically collected samples brings a challenge of 201 the unknown fasting state. The control cohort contained samples collected in the fasted state per 202 ADRC and EHBS protocols, but the AD cohort included many who had no collected fasting state 203 information and consist of samples collected in both fasted and non-fasted states. Therefore, to allow a direct comparison of the control and AD groups, we assessed the estimated subject 204 205 fasting state using our previously published predictive model [19]. As expected, control group 206 was predicted to contain mostly fasted subjects (Figure S1). Out of 133 control subjects, 105 (i.e. 79%) were predicted as fasted, while 17 (i.e. 12%) as non-fasted, with a probability of >60% 207 and 11 (i.e. 8%) had a fasting state probability of <60%. Out of 148 AD subjects, 60 (i.e. 40%) 208 were predicted as fasted and 81 (i.e. 55%) as non-fasted, with a probability of >60% and 7 (5%) 209 had a fasting state probability of <60%. Fifty percent of detected metabolites manifested 210 difference between predicted fasted and non-fasted AD subjects in plasma and only minimal 211 differences were observed in CSF (Table S2). 212

213

214 Cytochrome P450/soluble epoxide hydrolase metabolism is elevated in AD subjects: We

compared plasma and CSF lipid mediator concentrations between the control and the AD groups,
using only estimated fasted subjects with probability>60% for plasma. In plasma, we detected 42
oxylipins (85 measured), 5 PUFAs (5 measured), 17 endocannabinoids (22 measured), 3

218	NSAIDs (4 measured), 19 bile acids (23 measured) and 8 steroid hormones (8 measured). The
219	mean values and p-values for t-tests and two-way ANOVA interactions for all detected
220	metabolites are provided in Table S3. Plasma group-fold differences in the oxylipin,
221	endocannabinoids and PUFAs, projected onto their metabolic pathway, are presented in Figure
222	1. The largest differences were observed in the long chain omega-3 PUFA metabolism. Both
223	EPA and DHA enzyme derived mono-alcohols (5-LOX-derived 5-HEPE and 4-HDoHE and 12-
224	LOX-derived 12-HEPE and 14-HDoHE) were lower (1.5-fold in average) in the AD group,
225	when compared to the control. On the other hand, the sEH EPA metabolite 17,18-DiHETE, was
226	3-fold higher in the AD group. In the AD group, the AA pathway manifested lower levels of the
227	COX derived prostaglandins PGF2 α and PGD2 (1.6-fold average). Additionally, the AD group
228	showed lower levels of acylethanolamides (1.5-fold in average) derived from dihomo-gamma-
229	linolenic acid (DGLEA), AA (AEA), docosatetraenoic acid (DEA), DHA (DHEA) and oleic acid
230	(OEA). Notable are also lower levels of autooxidation markers, particularly the EPA-derived 9-
231	HEPE (2-fold), linoleic acid (LA) -derived TriHOMEs (1.65-fold) and AA-derived isoprostanes
232	(1.3-fold) in AD group.

Fewer lipid mediators were detected in CSF than in plasma. Detected CSF lipid 233 mediators included 17 oxylipins, 5 PUFAs, 3 endocannabinoids, 14 bile acids and 6 steroids. The 234 mean values and p-values for t-tests and two-way ANOVA interactions are provided in Table 235 S4. CSF significant group-fold differences in the level of oxylipin, endocannabinoids and 236 237 PUFAs, projected onto their metabolic pathway, are presented in Figure 2. In this matrix, the largest differences were observed in the LA CYP metabolic pathway, where both epoxy and 238 dihydroxy FA, products of CYP and subsequent sEH metabolism, were higher in the AD group 239 240 when compared to the control: epoxide average 1.5-fold; diol average 1.3-fold. All PUFAs from

both omega-3 and omega-6 pathway were lower in the AD group, although the difference was
only 1.2-fold on average. Additionally, AD group manifested 1.5-folds lower level of OEA and
1.3-fold lower level of the EPA-derived 14,15-DiHETE.

244 While few differences were observed in plasma and CSF bile acid levels between control and AD subjects, numerous differences were present in the specific bile acid ratios (Table 1). 245 246 Figure S2 shows bile acids metabolic pathway together with their median plasma levels to help understand the biological aspects of specific bile acid ratios. In plasma, the AD group was 247 248 characterized by lower levels of cholic acid (CA), a product of the neutral bile acids synthesis 249 pathway, while chenodeoxycholic acid (CDCA), a product of the acidic pathway was unchanged. This difference becomes even more pronounced when looking at the CA/CDCA ratio. On the 250 251 other hand, the difference between neutral and acidic pathway was not present in downstream metabolites, when comparing the secondary unconjugated bile acids ratio, like deoxycholic 252 acid/(lithocholic acid + ursodeoxycholic acid) (DCA/(LCA+UDCA)) or the most abundant 253 primary conjugated derivatives glycocholic acid/glycochenodeoxycholic acid (GCA/GCDCA); 254 Table S3. Of note, small differences between the neutral and acidic pathway were observed in 255 the low abundance taurine conjugates of the secondary bile acids 256 257 taurodeoxycholic/taurolithocholic acid (TDCA/TLCA). Difference in conjugation ratio (more conjugates than the substrate) was observed in the neutral synthesis pathway (GDCA/DCA and 258 GCA/CA) but not in the acidic synthesis pathway. Differences between the neutral and acidic 259 260 synthesis pathway were also observed in the conversion of the primary to secondary bile acids. The ratio of downstream products to their precursor in the neutral pathway was higher in the AD 261

group in the case of DCA/CA, TDCA/CA and GDCA/CA, but not in parallel acidic pathway

263 metabolites (i.e. LCA/CDCA, UDCA/CDCA).

264	CSF manifested few differences in bile acids and their ratios. The AD group had 1.3-fold
265	higher levels of GLCA and 1.4-fold higher level of T-a-MCA. Additionally, AD group had lower
266	ratio of GCDCA/GLCA (1.3-folds, Table S4).

- 267 Of those measured, only a few steroid hormones showed different levels between AD and
- the control. In plasma, dehydroepiandrosterone sulfate (DHEAS) and progesterone were lower in
- AD group (1.9 and 1.7-folds respectively). Additionally, testosterone and the
- 270 testosterone/progesterone ratio showed significant gender x group interaction. Females AD
- subjects showed 1.4-fold lower testosterone, when compared to females controls, but no
- differences were observed in males. On the other hand, the testosterone/progesterone ratio was 2-
- 273 fold higher in AD male subjects compared male controls. Testosterone/progesterone ratio
- 274 differences were not observed in females.
- In CSF, only corticosterone showed a significant difference between AD and the control group,
- however, the magnitude of the-fold difference only ~ 1.1 .
- 277

278 Relation between CSF and plasma AD markers.

In the current study, matched plasma and CSF samples were collected, allowing an assessment of
the relationships between metabolites in these pools. Spearman's p rank order correlation
between plasma and CSF lipid mediator levels are shown in Table 2. The associations were
distinct by metabolite classes, with oxylipins showing only 2 of 15 significant correlations, while
bile acids and steroids showing 14 of 18 significant correlations. Correlations within PUFA and
PUFA ethanolamide were also apparent for the long chain omega 3 species (DHA EPA and
DHA ethanolamide) but not others.

286	Next, we used partial least square discriminant analysis (PLS-DA) to illustrate the
287	relationship between plasma and CSF AD markers (Figure 3). The analysis showed that
288	discrimination between control and AD was dominated by the plasma metabolites. Fifteen
289	plasma metabolites (and their ratios) manifested variable importance in projection (VIP) score
290	>1.4 compared to only 4 CSF metabolites. The discrimination between AD and the control group
291	was characterized by higher plasma 17,18-DiHETE (VIP = 2.16) and CSF EpOMES (VIP = 1.95
292	and 1.58 for the $12(13)$ and $9(10)$ isoforms respectively) and lower levels of the
293	acylethanolamide ratios including both DHEA/LEA and DEA/LEA in plasma and both plasma
294	and CSF OEA/LEA. Plasma and CSF OEA/LEA manifest similar discriminatory power based on
295	their proximity on the loading plot. On the other hand, plasma 17,18-DiHETE and CSF EpOMEs
296	occupied distinct parts of the loading plot, suggesting distinct discriminatory properties. The
297	VIPs for each metabolite are provided in the Table S5.

298

299 Fatty acid ethanolamides and CYP/sEH metabolites are strong AD predictors in both plasma

and CSF. We used predictive modeling to investigate how well plasma and CSF metabolites can 300 report AD status. Plasma lipid mediators generated stronger models than those in CSF with area 301 under the receiver operator characteristic curves (ROC AUC) of 0.924 vs. 0.824, with the two 302 models consisting of distinct metabolites (Figure 4). However, in both matrices, the strongest 303 predictors belonged to the same two metabolic pathways, the acyl ethanolamides and CYP/sEH 304 pathway. Plasma predictors included ethanolamides (OEA and DEA normalized to the LEA 305 306 level), the 12,13-DiHOME/EpOME an indicator of sEH activity [27] and sEH metabolite of AA 307 (14,15-DiHETrE). In CSF, the strongest predictors included OEA/LEA and the linoleate-derived epoxides 12(13)-EpOME and 9(10)-EpOME. When plasma and CSF markers were combined in 308

309	predictive model efforts, the resulting model consisted uniquely of ethanolamides, including
310	plasma long chain PUFA ethanolamides (DEA/LEA and DHEA/LEA) and CSF OEA/LEA. This
311	model resulted in the ROC AUC of 0.889.
312	For all 3 models, ethanolamides OEA, DEA and DHEA were stronger predictors when
313	used as a ratio to LA derived ethanolamide – LEA. LEA itself was not different between AD and
314	the control group in either plasma or CSF (Figure 1 and Figure 2) unlike OEA, DEA and
315	DHEA. Therefore, LEA likely serves as a surrogate for the general acyl-ethanolamides level and

adjustment of other ethanolamides by LEA lowers intra-individual variability.

317

318 *Lipid mediator–cognitive score associations in AD*. The AD cohort is characterized by a high 319 log(t-Tau/Aβ42) ratio and MoCA scores ranging from normal cognitive function to severe cognitive impairment (Figure S3). Taking advantage of the broad MoCA range, we investigated 320 lipid mediator associations with cognitive function in this group pathological levels of t-321 Tau/Aβ42. Additionally, since the AD cohort was represented by subjects in both fasted and non-322 fasted states, we stratified the analysis by fasting state for plasma samples (Table 3). In the 323 324 fasting state, PUFA oxidation markers, 5,15-DiHETE and 9-HETE were negatively associated with the MoCA score (although only 5,15-DiHETE passed FDR correction). 5,15-DiHETE can 325 have enzymatic or autooxidative origin, whereas 9-HETE is a strictly an autooxidative product. 326 5,15-DiIHETE correlated with 9-HETE in fasted subjects with an $R^2=0.415$ (n=60; p <0.001). In 327 non-fasted AD subjects, a strong positive association between the MoCA score and EPA-derived 328 329 ethanolamide (EPEA) as well as the levels of EPA and DHA were observed. Additionally, a positive correlation was detected between MoCA and the EPA-derived 17,18-DiHETE, the 330

331 DHA-derived 14-HDoHE and the 18 carbon PUFAs (LA and ALA), however, these did not pass
332 FDR correction.

333	In CSF, the linoleic acid derived epoxides 12(13)- and 9(10) -EpOMEs showed weak but
334	significant positive correlations with MoCA ($\rho > 0.2$, $p < 0.005$; Table 4). Additionally, positive
335	associations were observed between MoCA and DHA and DHA derived diol (19,20-DiHDoPE)
336	and conjugated bile acids GCA (and the ratio of GCA to GDCA and GCDCA), TCDCA and the
337	conjugated to unconjugated ratio for DCA and CDCA (GCA/GCDCA, GCDCA/CDCA and
338	TCDCA/CDCA). However, only linoleic acid epoxides passed the FDR correction.

339

340 **Discussion**

Metabolic disruptions influencing vascular physiology, inflammation and energy metabolism 341 342 have been reported to increase the risk of Alzheimer's disease, however whether these changes are independent risk factors or how they may interact has not been well established. If novel 343 biomarkers of AD can be identified within these domains, they could not only provide useful 344 screening and risk assessment tools but may also provide insight into connections between 345 metabolism and neurodegenerative diseases. To this end, we performed a comprehensive 346 analysis of plasma and CSF lipid mediators, endogenous regulators of multiple processes 347 including inflammation and energy metabolism and described their associations with AD and 348 cognitive function. In the process, we identify clear differences between AD and healthy 349 350 controls in two metabolic pathways, CYP/sEH and fatty acids-derived ethanolamides, and subtle differences in bile acids and steroids. 351

AD-associated differences in plasma bile acid were in agreement with previously 352 reported analyses of The Religious Orders Study and the Rush Memory and Aging Project 353 (ROS/MAP) cohort [16]. These included lower levels of CA and the CA:CDCA ratio in AD, 354 suggesting that the neutral bile acid synthesis pathway could be affected in AD. There are few 355 studies regarding the shift between neutral and acidic BA synthesis, one of them reporting an 356 357 increase in neutral/acidic pathway products ratio in nonalcoholic steatohepatitis [28]. However, the biological relevance of this difference in terms of AD is yet to be determined. Interestingly, 358 we previously reported associations between postprandial bile acids and cognition, with few 359 360 associations in the fasting state [19]. Considering that the current manuscript focuses on AD related differences in the fasting state, further studies probing postprandial bile acid metabolism 361 and AD are suggested. Interestingly, several bile acid and steroid differences in AD were gender 362 363 specific. Few studies reports gender specific action of TUDCA and UDCA on ER stress markers in rodent model for the prion disease [29]. These findings further support the importance of 364 365 gender focused approaches when investigating cholesterol-derived metabolism in the context of AD, as established with regards to the links between ApoE4 and AD risk in post-menopausal 366 women [30]. 367

With respect to fatty acid metabolism, our study identified substantial AD-associated elevations in CYP/sEH pathway products and lower levels of acylethanolamides in both plasma and CSF, although different elements of these pathways were affected in plasma and CSF. Oxylipin and endocannabinoid levels show no association between plasma and CSF, suggesting independent regulation of these pools. Likewise, CYP/sEH metabolites of plasma and CSF manifest distinct discriminatory power in PLS-DA models of AD. On the other hand, CSF and plasma acylethanolamides seem to manifest similar AD discriminatory power and can be

substituted in the AD predictive model. These findings are consistent with previous reports
implicating both CYP/sEH metabolites and acylethanolamides as important regulators of

inflammation in neurodegenerative disorders [10, 31, 32].

378 In the CYP/sEH pathway, polyunsaturated fatty acids are converted to anti-inflammatory and vasodilating epoxy fatty acids by CYPs, which are further metabolized to pro-inflammatory 379 380 and vasoconstricting diols by sEH, a process primarily recognized in cardiovascular disease [33]. 381 In the current study, we found higher plasma level of the EPA sEH metabolite 17,18-DiHETE in 382 AD patients, but only slight difference in the parallel AA metabolites were observed. Notably, 383 EPA metabolites derived from LOX pathways were lower in AD patients, suggesting that the observed differences are not a result of differential omega-3 fatty acid intake, but rather specific 384 385 enhancement in sEH-dependent EPA metabolism. Omega-3 sEH metabolites are particularly potent regulators of the cardiovascular system, especially blood vessel tone and vascular 386 inflammation [34] and sEH inhibitors have been suggested to improve outcomes for both 387 cardiovascular [35] and neurodegenerative diseases [36]. Clinical associations between 388 cardiovascular disease and AD have been reported, where the regulation of a vascular tone and 389 blood flow play a role in both pathologies [37]. Additionally, we previously reported plasma 390 391 EPA sEH metabolites to be negatively associated with perceptual speed in cognitively normal subjects [19]. Therefore, the current findings further support involvement of vascular 392 393 dysfunction in AD, perhaps through alterations to the blood brain barrier and vascular-related 394 inflammatory signaling, with overlapping molecular mechanisms leading to cardiovascular and neurodegenerative pathologies. When considering these shifts in oxylipin profiles, it is 395 important to remember that an epoxides reservoir is generated by esterification into phospholipid 396 membranes [38], whereas diols are not readily reincorporated into the membranes and rapidly 397

398	appear in the free pool and are actively excreted from cells [39]. Since tissue esterified lipid
399	mediators were not evaluated in these samples, it is difficult to know whether the observe
400	difference in EPA diol was due to an increased production of CYP/sEH metabolites or increased
401	clearance of membrane bound EPA epoxides, and future studies are needed to resolve this issue.
402	In contrast to plasma, CSF showed higher levels of LA-derived epoxides, along with a
403	moderate increase in LA-diols, but not CYP/EH metabolites of longer chain PUFAs. The source
404	of the CSF metabolites is likely tied to the central nervous system, and linoleate-derived
405	oxylipins have been identified as the dominant form in the developing rat brain [40]. Like long
406	chain PUFAs, LA-derived epoxides and diols can also modulate vascular tone [41] and multiple
407	studies point towards their cytotoxic and pro-inflammation nature. However most of these
408	studies used concentrations greatly exceeding physiological levels [42] and cytotoxic effects
409	were sEH-dependent, pointing towards LA diols as cytotoxic agents [43]. Interestingly, LA
410	CYP/sEH metabolites elevated in the spinal tissue of burn victims were shown to activate the
411	transient vanilloid receptor type 1 (TRPV1) [44]. Activation of the TRPV1 can rescue neuronal
412	function from A β -induce impairment [45] and can alleviates cognitive and synaptic plasticity
413	impairments in the APP23/PS45 mouse model of AD [46]. Considering that acylethanolamides
414	are also potent activators of the TRPV1 [47], increased LA CYP metabolites may compensate
415	for the AD-related decrease in these ethanolamides. This hypothesis is supported by positive
416	correlation of CSF LA-epoxides with the MoCA score in the AD patients, suggesting elevation
417	of epoxy fatty acids in the central nervous system being potentially beneficial in AD. It is
418	important to mention that the transportation of oxylipins in CSF is poorly understood. In plasma,
419	the majority of oxylipins are transported as complex lipid esters in lipoproteins, with different
420	lipoproteins manifesting distinct oxylipin compositions [48]. Therefore, the potential for

421 lipoprotein-dependent oxylipin transport within CSF specific HDL particles [49] is particularly
422 intriguing and warrants further investigation.

423 Together the CSF and plasma results implicate changes in both peripheral and central 424 CYP/sEH metabolism in association with AD and cognitive impairment. These conclusions are consistent with previous reports of single nucleotide polymorphisms (SNPs) in the CYP2J2 425 426 promoter region that reduces gene expression by ~50% that appears to increase the ApoE4-427 independent AD risk [50]. Several functional SNPs are also known to influence sEH activity 428 and/or expression and influence disease risk [51]. Relevant to AD-associated pathologies, loss of 429 function sEH mutations protect neurons from ischemia-induced death [52] and may alter the risk of vascular cognitive impairment [53]. Additionally, postmortem brains from human subjects 430 431 with AD show higher sEH levels, when compared to the healthy controls, and sEH inhibitors can reverse microglia and astrocyte reactivity and immune pathway dysregulation in mouse AD 432 models [31]. Additionally, brain sEH was positively associated with AD in a replicated protein 433 434 wide-association study of AD [54]. Therefore, reducing sEH function appears to be protective, and supports sEH as a valuable therapeutic target for the treatment and investigation of neuro-435 inflammatory pathologies including AD. 436

Both plasma and CSF acylethanolamides were lower in AD, with both PLS-DA and
predictive model identifying OEA as the strongest predictor of AD in the current cohort.
Acylethanolamides are generally considered anti-inflammatory [55] and neuroprotective [56]
and were previously implicated in neuroinflammatory processes [57]. Their neuroprotective
action is mediated by activation of the CB1 and CB2 receptors [58] and TRPV1, involved in the
acute and inflammatory pain signals in periphery [59]. Some acylethanolamides, like OEA, are
also peroxisome proliferator-activated receptor (PPAR) α agonist [58] and regulate satiety and

444	sleep with both central and peripheral anorexigenic effects. Notably, sleep disturbances
445	themselves have been reported to be a risk factor for AD [60], and the identified reductions in
446	CSF OEA would be consistent with such a physiological manifestation [61]. A recent study also
447	suggested that the EPA-derived ethanolamide (EPEA) is a potential PPAR γ agonist [62], a
448	transcription factor known for its neuroprotective and anti-inflammatory action [63].
449	Interestingly, non-fasting levels of EPEA showed positive association with MoCA in AD
450	patients. This is in agreement with our previous findings of acylethanolamides in non-fasted
451	individuals, including EPEA, being positively associated with perceptual speed in cognitively
452	normal elderly individuals [19]. Literature provides conflicting results regarding both the levels
453	of acylethanolamides in biological fluids, as well as the expression of CB1 and CB2 receptors in
454	the context of AD [64]. Nevertheless, the body of literature suggests that exogenous
455	cannabinoids are potent activators of the CB1 and CB2 receptors with potential therapeutic
456	benefit for AD treatment, due to their neuroprotective and anti-inflammatory activity [65]. Our
457	data suggest acylethanolamide biology is altered in relation to both AD pathology as well as
458	cognition. However, future studies are needed to fully elaborate the role of these
459	endocannabinoids in AD pathology.

In conclusion, the current study shows AD related differences in CYP/sEH and acylethanolamide metabolism observed in both plasma and CSF. Strong predictive and discriminant models suggest their potential as biomarkers of AD-associated metabolic disruptions. This further supports the contention that a combination therapy reducing sEH activity while increasing acylethanolamide tone by either promoting production or reducing degradation could be a more effective strategy than targeting either pathway independently in treating multifactorial inflammatory diseases like AD [31]. Important questions remain regarding

467	the metabolic changes in the lipid mediators preceding pathological changes in tau and cognitive
468	decline. We have previously reported that plasma sEH metabolites of the long chain omega-3
469	PUFA were negatively associated and PUFA ethanolamides positively associated with
470	perceptual speed [19], mimicking the currently described AD related associations. While these
471	data suggest early alterations in these important regulatory pathways, a comprehensive analysis
472	of longitudinal metabolome changes in relation to cognition and tauopathies is warranted.
473	Combining assessments of dietary, lifestyle and genetic factors promoting these metabolic
474	changes offers the opportunity for novel risk factor discovery and the development of targeted
475	preventive measures.
476	
477	Limitations
4//	
478	This study was conducted using opportunistically collected samples with the fasting state
479	estimated using a previously developed predictive model [19] with an ~17% inherent
480	misclassification rate.
481	
487	Acknowledgements
483	Metabolomics data is provided by the Alzheimer's Disease Metabolomics Consortium (ADMC)
484	and funded wholly or in part by the following National Institute on Aging grants and
485	supplements, components of the Accelerating Medicines Partnership for AD (AMP-AD) and/or
486	Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD): NIA R01AG046171,
487	RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359,
488	U19AG063744 and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke

- 489 University in partnership with a large number of academic institutions. As such, the investigators
- 490 within the ADMC, not listed specifically in this publication's author's list, provided data but did
- 491 not participate in analysis or writing of this manuscript. A complete listing of ADMC
- 492 investigators can be found at: <u>https://sites.duke.edu/adnimetab/team/</u>. Metabolomics data and
- 493 pre-processed data are accessible through the AMP-AD Knowledge Portal
- 494 (https://ampadportal.org). The AMP-AD Knowledge Portal is the distribution site for data,
- analysis results, analytical methodology and research tools generated by the AMP-AD Target
- 496 Discovery and Preclinical Validation Consortium and multiple Consortia and research programs
- 497 supported by the National Institute on Aging. Additional support was provided by Emory ADRC
- 498 P30 AG066511 awarded to Allan I. Levey, Emory EHBS R01 AG070937 awarded to James J.
- 499 Lah and USDA Intramural Projects 2032-51530-022-00D and 2032-51530-025-00D awarded to
- 500 John W. Newman. The USDA is an equal opportunity employer and provider.

501 Conflicts of Interest: none

- 502 Kaddurah-Daouk is an inventor on several patents in the field of metabolomics and holds equity
- in Metabolon Inc which was not involved in this study.

504 **References**

506	1.	Alkan, E., et al., Metabolic syndrome alters relationships between cardiometabolic variables,
507		cognition and white matter hyperintensity load. Sci Rep, 2019. 9 (1): p. 4356.
508	2.	Bosia, M., et al., Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of
509		Metabolic Syndrome on Cognitive Remediation's Outcome. Front Psychiatry, 2018. 9: p. 647.
510	3.	Monthe-Dreze, C., et al., Maternal obesity and offspring cognition: the role of inflammation.
511		Pediatr Res, 2019. 85 (6): p. 799-806.
512	4.	Gabbs, M., et al., Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. Adv
513		Nutr, 2015. 6 (5): p. 513-40.
514	5.	Nayeem, M.A., Role of oxylipins in cardiovascular diseases. Acta Pharmacol Sin, 2018. 39(7): p.
515		1142-1154.

516 517 518	6.	Huang, C.C., et al., Association of Arachidonic Acid-derived Lipid Mediators with Subsequent Onset of Acute Myocardial Infarction in Patients with Coronary Artery Disease. Sci Rep, 2020. 10 (1): p. 8105
510 519 520	7.	Ma, H. and M.E. Patti, <i>Bile acids, obesity, and the metabolic syndrome.</i> Best Pract Res Clin Gastroenterol 2014 28 (4): p. 573-83
520 521 522	8.	Bellocchio, L., et al., <i>The endocannabinoid system and energy metabolism</i> . J Neuroendocrinol, 2008. 20 (6): p. 850-7
523 524	9.	Zou, S. and U. Kumar, Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018, 19 (3).
525 526	10.	Chiurchiu, V., et al., <i>The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases.</i> Prog Neuropiol, 2018. 160 : p. 82-100.
527	11.	Chiang, J.Y., <i>Bile acid metabolism and signaling</i> . Compr Physiol, 2013. 3 (3): p. 1191-212.
528	12.	Guo, C., W.D. Chen, and Y.D. Wang, TGR5, Not Only a Metabolic Regulator. Front Physiol, 2016.
529		7 : p. 646.
530	13.	Bazan, N.G., V. Colangelo, and W.J. Lukiw, Prostaglandins and other lipid mediators in
531		Alzheimer's disease. Prostaglandins Other Lipid Mediat, 2002. 68-69: p. 197-210.
532	14.	Kao, Y.C., et al., Lipids and Alzheimer's Disease. Int J Mol Sci, 2020. 21 (4).
533	15.	Miyazawa, K., et al., Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do
534		<i>MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?</i> Int J Mol Sci, 2020. 21 (16).
535	16.	MahmoudianDehkordi, S., et al., Altered bile acid profile associates with cognitive impairment in
536		Alzheimer's disease-An emerging role for gut microbiome. Alzheimers Dement, 2019. 15 (1): p.
537	47	
538	17.	Baloni, P., et al., Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism
539	10	In Alzneimer's Disease. Cell Rep Med, 2020. 1(8): p. 100138.
540 571	18.	Ackerman, H.D. and G.S. Gernard, Bile Acias in Neurodegenerative Disorders. Front Aging
541	10	Revision 2010. 6 . p. 205. Borkowski K e.a. Serum metabolomic biomarkers of percentual speed in cognitively normal and
543	15.	mildly impaired subjects with fasting state stratification
544		https://doi.org/10.1101/2020.09.03.282343.2020
545	20.	Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain
546		<i>Studies.</i> Neuroepidemiology, 2019. 53 (3-4): p. 187-200.
547	21.	Shaw, L.M., et al., Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging
548		<i>initiative subjects.</i> Ann Neurol, 2009. 65 (4): p. 403-13.
549	22.	Hulstaert, F., et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau
550		<i>levels in CSF.</i> Neurology, 1999. 52 (8): p. 1555-62.
551	23.	Pedersen, T.L., I.J. Gray, and J.W. Newman, Plasma and serum oxylipin, endocannabinoid, bile
552		acid, steroid, fatty acid and nonsteroidal anti-inflammatory drug quantification in a 96-well plate
553		<i>format.</i> Anal Chim Acta, 2021. 1143 : p. 189-200.
554	24.	Agrawal, K., et al., Sweat lipid mediator profiling: a noninvasive approach for cutaneous
555		<i>research.</i> J Lipid Res, 2017. 58 (1): p. 188-195.
556	25.	Saito, K., et al., Characterization of Postprandial Effects on CSF Metabolomics: A Pilot Study with
557	26	Parallel Comparison to Plasma. Metabolites, 2020. 10 (5).
558	26.	Benjamini, Y. and Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful
559		Approuch to wuittiple resting. Journal of the Royal Statistical Society. Series B (Methodological),
561	27	133. 31(1), P. 203-300.
562	21.	disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Gonat. 2006. 15(10): n
563		1640-9.

564 28. Jahn, D. and A. Geier, Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force 565 or innocent bystanders? Hepatology, 2018. 67(2): p. 464-466. 29. 566 Grant, S.M. and S. DeMorrow, Bile Acid Signaling in Neurodegenerative and Neurological 567 Disorders. Int J Mol Sci, 2020. 21(17). Neu, S.C., et al., Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-568 30. 569 analysis. JAMA Neurol, 2017. 74(10): p. 1178-1189. 570 31. Ghosh A, e.a., Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer's disease is 571 resolved by a soluble epoxide hydrolase inhibitor. BioRxiv doi: 572 https://doi.org/10.1101/2020.06.30.180984. 573 32. Kodani, S.D. and C. Morisseau, Role of epoxy-fatty acids and epoxide hydrolases in the pathology 574 of neuro-inflammation. Biochimie, 2019. 159: p. 59-65. 575 Deng, Y., K.N. Theken, and C.R. Lee, Cytochrome P450 epoxygenases, soluble epoxide hydrolase, 33. and the regulation of cardiovascular inflammation. J Mol Cell Cardiol, 2010. 48(2): p. 331-41. 576 577 34. Ulu, A., et al., Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble 578 epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol, 579 2013. 62(3): p. 285-97. 580 35. Imig, J.D. and B.D. Hammock, Soluble epoxide hydrolase as a therapeutic target for 581 cardiovascular diseases. Nat Rev Drug Discov, 2009. 8(10): p. 794-805. 582 Wagner, K.M., et al., Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory 36. 583 and neurodegenerative diseases. Pharmacol Ther, 2017. **180**: p. 62-76. 584 37. Firoz, C.K., et al., An overview on the correlation of neurological disorders with cardiovascular 585 disease. Saudi J Biol Sci, 2015. 22(1): p. 19-23. 586 38. Klett, E.L., et al., Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces 587 cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin 588 secretion. J Biol Chem, 2013. 288(30): p. 21618-29. 589 39. Greene, J.F., et al., Metabolism of monoepoxides of methyl linoleate: bioactivation and 590 detoxification. Arch Biochem Biophys, 2000. 376(2): p. 420-32. 591 40. Hennebelle, M., et al., Linoleic acid-derived metabolites constitute the majority of oxylipins in the 592 rat pup brain and stimulate axonal growth in primary rat cortical neuron-glia co-cultures in a 593 sex-dependent manner. J Neurochem, 2020. 152(2): p. 195-207. 594 41. Takahashi, H., et al., [Leukotoxin, 9,10-epoxy-12-octadecenoate, causes vasodilation in isolated 595 pulmonary artery rings preconstricted with endothelin 1]. Nihon Kyobu Shikkan Gakkai Zasshi, 596 1992. **30**(3): p. 418-24. 597 Hildreth, K., et al., Cytochrome P450-derived linoleic acid metabolites EpOMEs and DiHOMEs: a 42. 598 review of recent studies. J Nutr Biochem, 2020. 86: p. 108484. 599 43. Moghaddam, M.F., et al., Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. 600 Nat Med, 1997. 3(5): p. 562-6. 601 44. Green, D., et al., Central activation of TRPV1 and TRPA1 by novel endogenous agonists 602 contributes to mechanical allodynia and thermal hyperalgesia after burn injury. Mol Pain, 2016. 603 12. 604 45. Balleza-Tapia, H., et al., TrpV1 receptor activation rescues neuronal function and network 605 gamma oscillations from Abeta-induced impairment in mouse hippocampus in vitro. Elife, 2018. 606 7. 607 Du, Y., et al., TRPV1 activation alleviates cognitive and synaptic plasticity impairments through 46. 608 inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer's disease. Aging Cell, 609 2020. 19(3): p. e13113.

610	47	Raboure S, et al. Novel endogenous N-acyl amides activate TRPV1-4 recentors RV-2 microalia
611	47.	and are regulated in brain in an acute model of inflammation Front Cell Neurosci 2014 8: n
612		105
613	48	Borkowski K et al Walnuts change lipoprotein composition suppressing TNEalpha-stimulated
614	10.	cytokine production by diabetic adinocyte 1 Nutr Biochem 2019 68 : n 51-58
615	49	Mahley, R.W. Central Nervous System Linoproteins: AnoF and Regulation of Cholesterol
616	45.	Metabolism Arterioscler Thromb Vasc Biol 2016 36 (7): n 1305-15
617	50	Yan H C et al. CYP212 rs890293 polymorphism is associated with suscentibility to Alzheimer's
618	50.	disease in the Chinese Han nonulation Neuroscience Letters 2015 593 : n 56-60
619	51.	Srivastava, P.K., et al., Polymorphisms in human soluble enoxide hydrolase: effects on enzyme
620	51	activity enzyme stability and quaternary structure. Arch Biochem Biophys. 2004. 427 (2): p. 164-
621		9.
622	52	Koerner, LP., et al., Polymorphisms in the human soluble enoxide hydrolase gene FPHX2 linked to
623	52.	neuronal survival after ischemic iniury. I Neurosci. 2007. 27 (17): p. 4642-9.
624	53.	Nelson, J.W., et al., Role of soluble epoxide hydrolase in age-related vascular cognitive decline.
625		Prostaglandins Other Lipid Mediat, 2014. 113-115 : p. 30-7.
626	54.	Wingo, A.P., et al., Integrating human brain proteomes with genome-wide association data
627		implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet, 2021. 53(2): p. 143-146.
628	55.	Turcotte, C., et al., Regulation of inflammation by cannabinoids, the endocannabinoids 2-
629		arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol,
630		2015. 97 (6): p. 1049-70.
631	56.	Petrosino, S. and V. Di Marzo, The pharmacology of palmitoylethanolamide and first data on the
632		therapeutic efficacy of some of its new formulations. Br J Pharmacol, 2017. 174(11): p. 1349-
633		1365.
634	57.	Saito, V.M., R.M. Rezende, and A.L. Teixeira, Cannabinoid modulation of neuroinflammatory
635		disorders. Curr Neuropharmacol, 2012. 10(2): p. 159-66.
636	58.	Bradshaw, H.B. and J.M. Walker, The expanding field of cannabimimetic and related lipid
637		<i>mediators.</i> Br J Pharmacol, 2005. 144 (4): p. 459-65.
638	59.	Bradshaw, H.B., S. Raboune, and J.L. Hollis, <i>Opportunistic activation of TRP receptors by</i>
639		endogenous lipids: exploiting lipidomics to understand TRP receptor cellular communication. Life
640		Sci, 2013. 92 (8-9): p. 404-9.
641	60.	Li, K., et al., Interactions between sleep disturbances and Alzheimer's disease on brain function: a
642		preliminary study combining the static and dynamic functional MRI. Sci Rep, 2019. 9 (1): p.
643	~ ~	19064.
644	61.	Koethe, D., et al., Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. J
645	62	Neural Transm (Vienna), 2009. 116 (3): p. 301-5.
646	62.	Giordano, C., et al., <i>n-3 Polyunsaturated Fatty Acia Amides: New Avenues in the Prevention and</i>
647 648	62	Villanal S. Balas of Paravisama Braliferator, Activated Pasanter Camma on Brain and Parinhard
648 640	63.	Villapol, S., Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral
649 650	64	Porry A.L. et al. Endocannabinoid system alterations in Alzheimer's disease: A systematic
651	04.	review of human studies. Brain Pos. 2020. 17/0 : p. 147125
652	65	Aso E and L Ferrer Canadinaids for treatment of Alzheimer's disease: moving toward the
653	05.	clinic Front Pharmacol 2014 5: p 37
654	66.	Pedersen, T.L. and J.W. Newman, Establishing and Performing Targeted Multi-residue Anglysis
655		for Lipid Mediators and Fatty Acids in Small Clinical Plasma Samples. Methods Mol Biol. 2018.
656		1730 : p. 175-212.
		•

657 Figure legend

658

659	Figure 1. Plasma differences in fatty acids-derived oxylipins and endocannabinoids,
660	between control and AD group, projected on their metabolic pathway. Only differences with
661	the t-test p<0.05 and FDR correction at q=0.2 are shown. Network presents fatty acids metabolic
662	pathway, including saturates and monounsaturates (SFA and MUFA) and omega 3 and omega 6
663	fatty acids with oxylipins and endocannabinoids synthesis pathway. Both detected (black font)
664	and not-detected (gray font) metabolites are shown to visualize the coverage of the metabolic
665	pathway in our targeted assay and facilitate data interpretation. Although, for the clarity of the
666	figure, not all assay metabolites are displayed. The complete list of measured metabolites was
667	previously reported [66]. Oxylipin metabolizing enzymes are colored by their class: red -
668	lipoxygenase (LOX) and autoxidation pathway; blue - cytochrome p450 (CYP) epoxygenase;
669	$green-cyclooxygenase\ (COX);\ yellow-N-acylphosphatidyle than olamide-phospholip ase\ D.$
670	Node size represents the-fold difference, and the color represents the directionality of the
671	difference: orange – higher in AD; light blue – lower in AD. Key enzymes involved in metabolic
672	step are abbreviated next to the edge. Fads - fatty acid desaturase; Elov - fatty acids elongase;
673	sEH – soluble epoxide hydrolase; DH – dehydrogenase. Saturated and monounsaturated fatty
674	acids were not measured in this assay and are indicated only to visualize precursors for measured
675	oxylipins and endocannabinoids. Group means for all metabolites together with corresponding t-
676	test p-values are provided in the Table S3.

678	Figure 2. CSF differences in fatty acids-derived oxylipins and endocannabinoids, between
679	control and AD group, projected on their metabolic pathway. Only differences with the t-
680	test p<0.05 and FDR correction at q=0.2 are shown. Network presents fatty acids metabolic
681	pathway, including saturates and monounsaturates (SFA and MUFA) and omega 3 and omega 6
682	fatty acids with oxylipins and endocannabinoids synthesis pathway. For the clarity purposes,
683	only metabolites detected in CSF are shown. Oxylipin metabolizing enzymes are colored by
684	their class: red – lipoxygenase (LOX) and autoxidation pathway; blue – cytochrome p450 (CYP)
685	epoxygenase; green - cyclooxygenase (COX); yellow - N-acylphosphatidylethanolamide-
686	phospholipase D. Node size represents the-fold difference, and the color represents the
687	directionality of the difference: orange – higher in AD; light blue – lower in AD. Key enzymes
688	involved in metabolic step are abbreviated next to the edge. Fads - fatty acid desaturase; Elov -
689	fatty acids elongase; sEH – soluble epoxide hydrolase; DH – dehydrogenase. Saturated and
690	monounsaturated fatty acids were not measured in this assay and are indicated only to visualize
691	precursors for measured oxylipins and endocannabinoids. Group means for all metabolites
692	together with corresponding t-test p-values are provided in the Table S4.

693

Figure 3. Relation between plasma and CSF predictors of AD. Partial least square
discriminant analysis (PLS-DA) of AD vs control, utilizing metabolites from both plasma and
CSF in predicted fasted samples. Treatment group discrimination is shown by the SCORES
(inset) with a plain of discrimination indicated by dashed read line, while metabolites weighting
in group discrimination are shown by the LOADINGS. Loading node color indicates metabolite
origin (pink for plasma and blue for CSF). Loading node size indicates metabolite variable

700	in a stand in the standing (i.e. VID). A standing standard from the standard standard to stand the life standard
/00	importance in projection (i.e. VIP). Analysis was performed with all measured metabolites,
701	including specific ratios, but only those with VIP \geq 1.4 are displayed for clarity purpose.
702	
703	Figure 4. Predictive model for AD with plasma and CSF metabolites. Predictive model built
704	independently for plasma (left) and CSF (middle) and plasma+CSF (right). Effect summery
705	shows metabolite model components, sorted by their contribution to the model, with key
706	pathway colored in yellow (fatty acids ethanolamides) and blue (cytochrome p450/soluble
707	epoxide hydrolase pathway). Receiver operating characteristics (ROC) curve for the training set,
708	together with the area under the curve (AUC) and the n for the training (T) and the validation (V)
709	cohorts, are showed in the bottom panel. Metabolite selection through the stepwise logistic
710	regression model together with validation cohort parameters are provided in the Table S6.
711	
712	
/12	
713	
714	
715	
710	
10	
717	
718	
719	

720 Tables

721 Table 1. Differences in bile acids metabolites and their specific rations between control and AD

- 722 group. Means are expressed in nM or as a ratio of the concentrations. Metabolites and their ratio are
- stratified by the metabolic affiliations. All tested bile acids and their ratios are presented in the Table S3.

Matabalita	Dyvalue	Mean [95%CI]			
Wietabolite	P value	Control	AD		
	Neutral vs acidic synthesis pathway				
CA	0.0321	27.4 [20.8 - 36.2]	19.3 [13.6 - 27.4]		
CDCA	0.978	38.7 [29.2 - 51.5]	46.7 [32.6 - 66.9]		
CA/CDCA	0.0008	0.707 [0.571 - 0.876]	0.363 [0.271 - 0.487]		
GCDCA/GDCA	0.5	2.08 [1.66 - 2.61]	1.97 [1.51 – 2.57]		
TDCA/TLCA	0.0114	1.33 [1.1 - 1.62]	1.81 [1.49 - 2.21]		
	Conjugatio	on, neutral synthesis pathwo	ay		
GDCA/DCA	0.0031	0.719 [0.604 - 0.856]	1.05 [0.836 - 1.33]		
TDCA/DCA	0.1	0.0605 [0.0467 - 0.0783]	0.0777 [0.0556 - 0.109]		
GCA/CA	0.0104	2.52 [1.86 - 3.39]	4.13 [2.84 - 6.01]		
TCA/CA	0.076	0.506 [0.358 - 0.716]	0.711 [0.434 - 1.16]		
	Conjugati	ion, acidic synthesis pathwa	<i>IY</i>		
GUDCA/UDCA	0.7	0.546 [0.341 - 0.876]	0.515 [0.334 - 0.793]		
TUDCA/UDCA	0.746	2.83 [1.93 - 4.17]	2.04 [1.33 - 3.13]		
GCDCA/CDCA	0.491	8.15 [6.21 - 10.7]	8.36 [5.68 - 12.3]		
TCDCA/CDCA	0.644	0.734 [0.53 - 1.01]	0.687 [0.433 - 1.09]		
TLCA/LCA	0.961	0.282 [0.2 - 0.396]	0.252 [0.182 - 0.347]		
GLCA/LCA	0.721	0.711 [0.53 - 0.955]	0.749 [0.552 - 1.02]		
Conversion of primary to secondary. Gut metagenome activity					
DCA/CA	0.0459	8.01 [5.8 - 11.1]	12 [7.89 - 18.1]		
TDCA/CA	0.0056	0.469 [0.309 - 0.711]	0.906 [0.517 - 1.59]		
GDCA/CA	0.0007	5.76 [4.01 - 8.27]	12.5 [7.71 - 20.2]		
LCA/CDCA	0.451	0.66 [0.419 - 1.04]	0.589 [0.42 - 0.825]		
UDCA/CDCA	0.691	1.39 [0.815 - 2.36]	1.94 [1.23 - 3.07]		
TUDCA	0.0275	1.07 [0.78 - 1.48]	1.92 [1.53 - 2.41]		

726 **Table 2.** Spearmans rank order correlation between plasma and CSF metabolites. Significant p

values are bolded.

Metabolite class	Metabolite	Spearman's p	P value
	PGF2a	-0.2	0.0746
	F2-IsoP	0.34	0.0019
	12_13-DiHOME	0.26	0.0223
	9_10-DiHOME	0.15	0.1810
	15_16-DiHODE	0.21	0.0625
S	14_15-DiHETrE	0.062	0.5830
ii	11_12-DiHETrE	0.11	0.3340
ylij	17_18-DiHETE	0.33	0.0027
)x)	19_20-DiHDoPE	0.16	0.1450
0	13-HODE	0.029	0.7970
	9-HODE	-0.054	0.6380
	13-HOTE	-0.014	0.9010
	9-HOTE	-0.051	0.6520
	12(13)-EpOME	0.0089	0.9380
	9(10)-EpOME	-0.028	0.8070
<u> </u>	OEA	-0.031	0.7820
EA	LEA	0.062	0.5860
A L	DHEA	0.51	0.0001
	LA	0.15	0.1860
V	ALA	0.2	0.0826
0F	AA	-0.049	0.6670
P	EPA	0.45	0.0001
	DHA	0.42	0.0001
	CDCA	0.51	0.0001
	UDCA	0.78	0.0001
	DCA	0.71	0.0001
	TCA	0.62	0.0001
ds	TCDCA	0.43	0.0001
aci	TUDCA	0.16	0.1570
le	TDCA	0.54	0.0001
Bil	GCA	0.36	0.0012
	GCDCA	0.19	0.0925
	GUDCA	0.47	0.0001
	GDCA	0.54	0.0001
	GLCA	-0.083	0.4670
	170H-PROG	0.58	0.0001
ids	Cortisol	0.3	0.0071
LO	Cortexolone	0.089	0.4340
Ste	corticosterone	0.51	0.0001
•1	Testosterone	0.81	0.0001

728 Table 3. Spearman's ρ rank order correlation between MoCA score and plasma lipid

729 mediators of the AD patients. Analysis stratified by predicted fasted state. Only correlations

with the p<0.05 are shown. P-values that passed FDR correction at q=0.2 are bolded.

	Fasted			Non-fasted		
	Metabolite	Spearman p	P value	Metabolite	Spearman p	P value
	5,15-DiHETE	-0.448	0.0005	EPEA	0.424	0.0003
	9-HETE	-0.338	0.0102	EPA	0.386	0.001
	13-KODE	-0.299	0.0238	DHA	0.338	0.0043
	DCA	-0.273	0.0398	17,18-DiHETE	0.3	0.0117
				4-HDoHE	0.269	0.0246
				LA	0.267	0.0254
				ALA	0.249	0.0373
				9-HETE	-0.246	0.0405
				8-HETE	-0.24	0.0459
731						
732						
733						
734						
735						
/ 33						
720						
/30						
737						
738						
739						
740						

741 Table 4. Spearman's ρ rank order correlation between MoCA score and CSF lipid mediators of

- 742 the AD patients. Only correlations with the p<0.05 are shown. P-values that passed FDR correction at
- 743 q=0.2 are bolded.

	Metabolite	Spearman p	P value
	12(13)-EpOME	0.279	0.0009
	9(10)-EpOME	0.24	0.0047
	19,20-DiHDoPE	0.21	0.0138
	GCA	0.207	0.0152
	DHA	0.203	0.0174
	GCA/GDCA	0.202	0.0182
	GCDCA/CDCA	0.19	0.026
	TDCA/DCA	0.19	0.0261
	GCA/GCDCA	0.18	0.0352
	TCDCA/CDCA	0.172	0.0441
	TCDCA	0.17	0.0468
744			
745			
-			
/46			
747			
740			
748			
749			
750			
/ 50			
751			
752			
753			
754			

755 Figures

756



758 Figure 1. Plasma differences in fatty acids-derived oxylipins and endocannabinoids, between

control and AD group, projected on their metabolic pathway.

760

761

762

763

764

765



768 Figure 2. CSF differences in fatty acids-derived oxylipins and endocannabinoids, between control

and AD group, projected on their metabolic pathway.



782

783 Figure 3. Relation between plasma and CSF predictors of AD

784



787 Figure 4. Predictive model for AD with plasma and CSF metabolites. Acylethanolamides

797 Supplemental figures

798



Figure S1. Distribution of subject's probability of being in a fasted state in the control and AD
groups. Colors shows 60% probability cutoffs for: red – fasted; blue – non-fasted.

802

799

803

804



807 Figure S2. Bile acids biosynthesis pathway. Node colors represent primary (blue) and secondary (dark red) bile acids. Node shape represent conjugated (diamond) and unconjugated 808 809 (oval) bile acids. Node size represents median concentration in the experimental cohort. Cholesterol (top of the pathway) is converted to primary bile acids along two pathways, neutral 810 and acidic [1]. Further, primary bile acids are secreted to gut, and portion of it being modify by 811 the gut bacteria to secondary bile acids. Primary and secondary bile acids are reabsorbed into the 812 blood stream and reenter the liver, where they are conjugated with amino acids glycine or 813 taurine. Conjugated bile acids are then being secreted back to the gut along with primary bile 814 815 acids. Gut bacteria can cleave conjugated amino acids off bile acids [2], and freed metabolites are recirculated. Therefore, plasma levels of conjugated bile acids can me a reflection of both 816 817 liver and gut bacteria activity. Refference: 1.Pandak, W.M. and G. Kakiyama, The acidic 818 pathway of bile acid synthesis: Not just an alternative pathway(). Liver Res, 2019. 3(2): p. 88-98; 819 2. Ridlon, J.M., et al., Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes, 2016. 7(1): p. 22-39. 820



Figure S3. Control and AD group MoCA and $\log(t-Tau/A\beta 42)$.